<DOC>
	<DOCNO>NCT02342314</DOCNO>
	<brief_summary>The study involve single dose LY3143753 LY3185643 , give injection abdomen . The study evaluate effect LY3143753 LY3185643 body . The study approximately 12 week participant , include screen . Screening require within 28 day prior start study . This study involve Part A ( LY3143753 ) Part B ( LY3185643 ) . Participants may enroll one part one dose level .</brief_summary>
	<brief_title>A Study LY3143753 LY3185643 Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Overtly healthy male female Are reliable willing make available duration study willing follow study procedure Are investigator site personnel directly affiliate study immediate family Are currently enrol clinical trial involve investigational product ( IP ) offlabel use drug device Have participate , within last 3 month , clinical trial Have know ongoing psychiatric disorder Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen History of/current phaeochromocytoma History of/current insulinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>